Power of Recursion O
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
May 29, 2024 15:27 ET | Recursion Pharmaceuticals
SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature...
Cytosurge Logo_cyan - RGB.png
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
May 29, 2024 08:30 ET | Cytosurge AG
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.
Cover Biotechnology Journal April 2024 - Cytosurge CellEDIT publication
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
May 29, 2024 02:30 ET | Cytosurge AG
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.
TOME-Logo-RGB.png
Tome Biosciences Presented Data on its Programmable Genomic Integration Technologies at ASGCT
May 10, 2024 06:00 ET | Tome Biosciences
Tome presented data updates on its programmable genomic integration technologies at ASGCT.
Caribou_logo.png
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024 16:05 ET | Caribou Biosciences, Inc.
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into...
fulllogo_transparent_nobuffer Aanastra.png
Aanastra Inc to Showcase its Peptide-RNA Therapeutics Technology in Multiple Presentations at the American Society for Gene and Cell Therapies (ASGCT) Annual Meeting 2024
May 02, 2024 06:30 ET | Aanastra Inc
Aanastra showcases its peptide-RNA therapeutics targeting p53, KRAS and BRCA-1 driven cancers, hemophilia A and PCSK9 for hypercholestrolemia at ASGCT
Caribou_logo.png
Caribou Biosciences to Participate in Upcoming Investor Conferences
May 01, 2024 16:05 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Caribou_logo.png
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
April 15, 2024 09:00 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract...
EpicBioCMYK300dpi.png
Epic Bio to Participate in a Fireside Chat at the Canaccord Genuity Genetic Medicine for Generalists
April 10, 2024 13:47 ET | Epic Bio
SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced that...
Caribou_logo.png
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
April 04, 2024 16:00 ET | Caribou Biosciences, Inc.
-- FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial...